Certain A Shares of WuXi AppTec Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-MAY-2021.
May 06, 2021
Share
Certain A Shares of WuXi AppTec Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-MAY-2021. These A Shares will be under lockup for 1101 days starting from 2-MAY-2018 to 7-MAY-2021.
Details:
Li Ge and Zhao Ning, the company's de facto controllers and the shareholders of the Company, G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited, Jiaxin Yuxiang Equity Investment Partnership LLP?G&C VII Limited, Shanghai Houshen Equity Investment Center LLP?Jiaxin Yumin Equity Investment Partnership LLP?Jiaxin Houyi Equity Investment Partnership LLP?Jiaxin Houyu Equity Investment Partnership LLP?Jiaxin Houzi Equity Investment Partnership LLP?Jiaxin Houjing Equity Investment Partnership LLP?Shanghai Houyong Equity Investment Center LLP?Shanghai Houzhen Equity Investment Center LLP?Shanghai Houxuan Equity Investment Center LLP?Shanghai Houyue Equity Investment Center LLP?Shanghai Houyao Equity Investment Center LLP?Shanghai Housong Equity Investment Center LLP?Shanghai Houling Equity Investment Center LLP, Fertile Harvest Investment Ltd,. Eastern Star Asia Investment Ltd. and L&C Investment Ltd have pledged not to transfer or entrust others to manage the company's shares held directly or indirectly to the issue before, nor part of the shares repurchased by the company, within 36 months from the date of the company's initial public offering of shares.
The shareholders of the Company Glorious Moonlight, Summer Bloo (I), WXAT BVI, ABG-WX Holding (HK), Jiashi Kanghen Equity Investment Partnership LLP?HCFII WX (HK) , Shanghai Jinyao Investment Management Co., Ltd.,Pearl WX HK, Yunfeng II, SCC Growth III,Guoshou Chenda,Brilliant Rich, LCH Investment Lt., Shenzhen Ping An Property Investment Co., Ltd., Tangshen Jinji Health Investment Partnership LLP, Shanghai Yunfeng Henyuan Equity Investment Center LLP, Ningbo Yunlong Equity Investment Center LLP, Ningbo Hongqi Equity Investment Center LLP and the management team of the Company have pledged not to transfer or entrust others to manage the company's shares held directly or indirectly to the issue before, nor part of the shares repurchased by the company, within 12 months from the date of the company's initial public offering of shares.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
WUXI APPTEC CO., LTD. 
